UBS AM
FULC icon

UBS AM’s Fulcrum Therapeutics FULC Stock Holding History

UBS AM’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.93K Buy
773
+64
+9% +$594 ﹤0.01% 3427
2025
Q4 		$8.02K Buy
+709
New +$7.21K ﹤0.01% 2895
2025
Q2 		– Sell
-703
Closed -$2.02K – 2655
2025
Q1 		$2.02K Buy
+703
New +$2.58K ﹤0.01% 2633
2023
Q3 		– Sell
-25,699
Closed -$73.2K – 2625
2023
Q2 		$73.2K Hold
25,699
– – ﹤0.01% 2655
2023
Q1 		$73.2K Buy
25,699
+10,899
+74% +$97.7K ﹤0.01% 2655
2022
Q4 		$108K Hold
14,800
– – ﹤0.01% 2490
2022
Q3 		$120K Hold
14,800
– – ﹤0.01% 2667
2022
Q2 		$72.5K Hold
14,800
– – ﹤0.01% 2662
2022
Q1 		$350K Buy
+14,800
New +$209K ﹤0.01% 2558

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

UBS AM's FULC Position: Q1 2026 in Review

UBS AM increased its Fulcrum Therapeutics (FULC) stake by 9% in Q1 2026, buying an estimated $594 and bringing the position to 773 shares worth $5.93K. The position accounts for ﹤0.01% of the portfolio, ranked #3427.

UBS AM first reported a position in FULC in Q1 2022 and has held it in 9 quarters since. The position peaked at $350K in Q1 2022. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • UBS AM held 773 shares of Fulcrum Therapeutics worth $5.93K as of Q1 2026.
  • UBS AM bought 64 Fulcrum Therapeutics shares in Q1 2026, an estimated $594.
  • Fulcrum Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q1 2026, its #3427 holding.
  • UBS AM first reported a position in Fulcrum Therapeutics in Q1 2022 and has held it in 9 quarters since.
  • UBS AM's Fulcrum Therapeutics position peaked at $350K in Q1 2022.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.